Larimar Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell-penetrating peptide technology platform for intracellular delivery of protein therapies. Founded in 2013 and headquartered in Bala Cynwyd, Pennsylvania, the company targets rare genetic disorders characterized by deficiencies in intracellular bioactive compounds, primarily Friedreich’s ataxia (FA), a progressive neurodegenerative disease caused by frataxin (FXN) deficiency. Its lead product candidate, nomlabofusp (previously CTI-1601), is a subcutaneously administered recombinant fusion protein designed to deliver FXN to mitochondria; nomlabofusp is currently advancing in a Phase 2 open-label extension (OLE) study evaluating daily dosing at 25 mg and 50 mg, with plans for a global Phase 3 trial and a Biologics License Application (BLA) submission in Q2 2026 seeking accelerated approval based on skin FXN levels as a surrogate endpoint. Larimar plans to expand its protein replacement therapy platform to additional rare diseases beyond FA. Recent developments include a $65.1 million public offering of common stock closed in July 2025 to fund nomlabofusp advancement; positive long-term OLE data announced in September 2025 showing 100% of participants (n=10) achieving carrier-level skin FXN after six months of daily dosing, consistent directional improvements in clinical measures like mFARS and 9-HPT, and treatment of 65 participants across studies; FDA selection for the START pilot program in 2024, removal of a partial clinical hold, and supportive guidance on BLA requirements including a safety database of at least 30 participants with six months exposure; publication of two peer-reviewed articles in July 2025 supporting nomlabofusp’s mechanism; and dosing of adolescents in a pediatric pharmacokinetic run-in study in January 2025, with recruitment ongoing for OLE expansion. Operations are primarily in the United States, with clinical sites activated globally for Phase 3 planning.
Company News
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)